Boston Scientific | Advancing Science For Life

It Takes a Culture of High Performance to Drive Strong Financial Results

Investors

Our track record of high performance:

$10.7
billion FY 2019 sales
11%
operational1 revenue growth in 2019
7%
organic1 revenue growth in 2019
13%
adjusted EPS1 growth in 20192
$1.58
adjusted EPS1 in 2019
380
adjusted operating margin1 basis point improvement since 2015
$2.0
billion adjusted free cash flow1 in 2019

1 Non-GAAP measure; excludes certain GAAP items. For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to our Financial Disclaimers and Non-GAAP Reconciliations.

2 Full year 2019 adjusted earnings per share growth of 13% excludes the 2018 net tax benefit of $0.07 from settling the IRS Stipulation of Settled Issues in the base.  By contrast, full year 2018 adjusted earnings per share of $1.47 includes such $0.07 net tax benefit.

Safe Harbor for forward-looking statements
This site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Connect with Boston Scientific Investor Relations

Investor relations contact

300 Boston Scientific Way
Mailstop M405
Marlborough, MA 01752
BSXInvestorRelations@bsci.com